GPx3 promoter hypermethylation is a frequent event in human cancer and is associated with tumorigenesis and chemotherapy response

Baishen Chen, Xi Rao, Michael G. House, Kenneth P. Nephew, Kevin J. Cullen, Zhongmin Guo

Research output: Contribution to journalArticle

61 Scopus citations


Glutathione peroxidase 3 (GPx3), a plasma antioxidant enzyme, maintains genomic integrity by inactivating reactive oxygen species (ROS), known DNA-damaging agents and mediators of cancer chemotherapy response. In this study, we demonstrate that loss of GPx3 expression by promoter hypermethylation is frequently observed in a wide spectrum of human malignancies. Furthermore, GPx3 methylation correlates with head and neck cancer (HNC) chemoresistance and may serve as a potential prognostic indicator for HNC patients treated with cisplatin-based chemotherapy. Our findings support the hypothesis that defects in the antioxidant system may contribute to tumorigenesis of a wide spectrum of human malignancies. GPx3 methylation may have implications in chemotherapy response and clinical outcome of HNC patients.

Original languageEnglish (US)
Pages (from-to)37-45
Number of pages9
JournalCancer Letters
Issue number1
StatePublished - Oct 1 2011



  • Antioxidant enzymes
  • Chemotherapy response
  • DNA methylation
  • Head and neck cancer
  • Prognosis

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this